LIXTW
Income statement / Annual
Last year (2024), Lixte Biotechnology Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Lixte Biotechnology Holdings, Inc.'s net income was -$3.59 M.
See Lixte Biotechnology Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$200,000.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$200,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$726,232.00
|
$898,100.00
|
$1.35 M
|
$1.74 M
|
$1.22 M
|
$820,906.00
|
$40,703.00
|
$467,258.00
|
$1.30 M
|
$2.09 M
|
| General & Administrative Expenses |
$2.85 M
|
$4.19 M
|
$4.96 M
|
$4.98 M
|
$2.01 M
|
$1.67 M
|
$2.10 M
|
$1.34 M
|
$833,782.00
|
$754,440.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.85 M
|
$4.19 M
|
$4.96 M
|
$4.98 M
|
$2.01 M
|
$1.67 M
|
$2.10 M
|
$1.34 M
|
$833,782.00
|
$754,440.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33,806.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$3.57 M
|
$5.09 M
|
$6.31 M
|
$6.72 M
|
$3.27 M
|
$2.49 M
|
$2.14 M
|
$1.81 M
|
$2.13 M
|
$2.85 M
|
| Cost And Expenses |
$3.57 M
|
$5.09 M
|
$6.31 M
|
$6.72 M
|
$3.27 M
|
$2.49 M
|
$2.14 M
|
$1.81 M
|
$2.13 M
|
$2.85 M
|
| Interest Income |
$7,048.00
|
$1,253.00
|
$11,195.00
|
$626.00
|
$5,232.00
|
$49,723.00
|
$4,923.00
|
$1,375.00
|
$183.00
|
$78.00
|
| Interest Expense |
-$16,821.00
|
$0.00
|
$8,875.00
|
$7,414.00
|
$3,674.00
|
$0.00
|
$4,923.00
|
$1,375.00
|
$183.00
|
$78.00
|
| Depreciation & Amortization |
$0.00
|
$5.09 M
|
$6.31 M
|
$6.72 M
|
$3.27 M
|
$2.49 M
|
$2.14 M
|
$1.81 M
|
$2.13 M
|
$205,773.00
|
| EBITDA |
-$3.57 M |
$3,206.00 |
-$1,054.00 |
-$7,951.00 |
$1,558.00 |
-$2.49 M |
$4,923.00 |
$1,375.00 |
$183.00 |
-$2.44 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-12.2
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-13.23
|
| Total Other Income/Expenses Net |
-$13,176.00
|
$3,207.00
|
-$1,054.00
|
-$7,951.00
|
$1,558.00
|
$49,723.00
|
$4,923.00
|
$1,375.00
|
$183.00
|
-$205,695.00
|
| Income Before Tax |
-$3.59 M
|
-$5.09 M
|
-$6.31 M
|
-$6.73 M
|
-$3.26 M
|
-$2.44 M
|
-$2.13 M
|
-$1.81 M
|
-$2.13 M
|
-$2.85 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-14.26
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$7,821.00
|
$6,788.00
|
-$1,558.00
|
-$49,723.00
|
-$9,846.00
|
-$1,809.79
|
-$2,134.92
|
-$78.00
|
| Net Income |
-$3.59 M
|
-$5.09 M
|
-$6.30 M
|
-$6.74 M
|
-$3.26 M
|
-$2.39 M
|
-$2.13 M
|
-$1.81 M
|
-$2.13 M
|
-$2.85 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-14.26
|
| EPS |
-1.59 |
-2.66 |
-4 |
-5 |
-2.89 |
-2.14 |
-2.18 |
-1.94 |
-2.68 |
-3.66 |
| EPS Diluted |
-1.59 |
-2.66 |
-4 |
-5 |
-2.89 |
-2.14 |
-2.18 |
-1.94 |
-2.68 |
-3.66 |
| Weighted Average Shares Out |
$2.25 M
|
$1.91 M
|
$1.58 M
|
$1.35 M
|
$1.13 M
|
$1.12 M
|
$979,935.00
|
$930,000.00
|
$797,000.00
|
$779,000.00
|
| Weighted Average Shares Out Diluted |
$2.25 M
|
$1.92 M
|
$1.58 M
|
$1.35 M
|
$1.13 M
|
$1.12 M
|
$979,935.00
|
$930,290.00
|
$797,930.00
|
$779,891.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
